Gene-editing technology company Inscripta said the USPTO granted the company its first patent covering systems using MAD7, the company’s first free CRISPR enzyme, as well as patent coverage for systems using another MADzyme, MAD2.
Inscripta also released new data run by external partners “showing MAD7 can edit mammalian cells.”
Inscripta CEO Kevin Ness said: “Today marks a major step forward in the gene-editing revolution we started seven months ago when we released our own, unique CRISPR enzyme (MAD7).
“We and our partners have shown that MAD7 is an effective tool in editing microbial and mammalian cells.
“All researchers, both academics and industrial scientists alike, can use MAD7 confidently, and Inscripta is committed to providing a license to its related patents for customers to perform free research and development using the enzyme.”
Inscripta said the new data “confirms the potential for using MADzymes in human therapeutic and diagnostic applications, as well as biological development and manufacturing in a wide array of cell lines.”